Navigation Links
Brain tumors: Tissue stem cell turning into tumor stem cell
Date:4/1/2010

The "cradle" of new neurons in the adult brain is well known. It is what is called the subventricular zone, a tissue structure lining the lateral ventricles. This is where neural or brain stem cells reside, which are responsible for generating new neurons if needed. For many years now, the subventricular zone has been suspected to be the origin of specific malignant brain tumors called gliomas, the most deadly type of which is glioblastoma.

Scientists from the divisions of Professor Dr. Gnther Schtz and Professor Dr. Peter Lichter at the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) have recently shown in mouse brains that brain stem cells in the subventricular zone are characterized by a specific molecule: Protein Tlx, a transcription factor, which stimulates the activity of various genes. In the adult animal, Tlx is expressed exclusively in brain stem cells. When the scientists switched off Tlx, there were no more detectable stem cells in the brain and the formation of new neurons ceased. Functioning of the stem cells thus appears to depend on the presence of this protein.

In their recent study, the teams headed by Gnther Schtz and Peter Lichter, jointly with Professor Dr. Guido Reifenberger of Dsseldorf University, have now tested the opposite case: What happens if the production of Tlx is increased? Using a molecular-biological trick, the investigators induced an overproduction of Tlx by the brain stem cells of mice. As a result, cell division activity in the subventricular zone increased, the cells left their habitual environment called stem cell niche, and started forming glioblastoma-like tissue lesions. In another experiment in which the researchers additionally switched off the p53 protein as an important cancer brake, invasively growing glioblastomas arose from the cancer precursors.

Moreover, the scientists discovered that stem cells with increased Tlx production stimulate the formation of new vessels. This enables the cells to migrate into distant brain regions and, thus, to generate the typical coral-like growth of glioblastoma.

"We recognize brain stem cells specifically by their Tlx production. If we boost it, the tissue stem cell turns into a cancer stem cell from which malignant glioblastomas arise. Therefore, we are now able, for the first time, to hold brain stem cells directly responsible for the formation of brain tumor stem cells," Gnther Schtz explains.

The researchers expect to be able to develop new therapies to treat glioblastoma on the basis of these results from fundamental cell biology research. Tlx seems to play its fatal role not only in mouse brains. Studying tumor tissue from glioblastoma patients, Lichter and Reifenberger discovered that the Tlx gene is often present in multiple copies and, thus, more Tlx protein is produced. "Apparently, human brain tumor stem cells also depend on Tlx. Therefore, we can now try to develop therapies that are directed very specifically against Tlx producing cells," said Schtz describing the next steps. The mice whose brain stem cells overproduce Tlx are an ideal model system for such investigations.


'/>"/>

Contact: Dr. Sibylle Kohlstdt
s.kohlstaedt@dkfz.de
Helmholtz Association of German Research Centres
Source:Eurekalert

Related biology news :

1. Impaired brain connections traced to schizophrenia mutation
2. New brain nerve cells key to stress resilience, UT Southwestern researchers find
3. Insulin-like signal needed to keep stem cells alive in adult brain
4. New understanding of proteins role in brain
5. New period of brain plasticity created with transplanted embryonic cells
6. Sex on the brain: Doublesex gene key to determining fruit fly gender
7. My brain made me do it
8. Psychopaths brains wired to seek rewards, no matter the consequences
9. The scientific brain
10. Which came first: Religion or the brain?
11. Ritalin boosts learning by increasing brain plasticity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
(Date:4/28/2016)... April 28, 2016 First quarter 2016:   ... 966% compared with the first quarter of 2015 The ... 589.1 M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) ... guidance is unchanged, SEK 7,000-8,500 M. The operating margin ...
(Date:4/15/2016)... 2016  A new partnership announced today will ... decisions in a fraction of the time it ... high-value life insurance policies to consumers without requiring ... Force Diagnostics, rapid testing (A1C, Cotinine and HIV) ... pressure, weight, pulse, BMI, and activity data) available ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... June, 23, 2016  The Biodesign Challenge (BDC), a ... ways to harness living systems and biotechnology, announced its ... in New York City . ... students, showcased projects at MoMA,s Celeste Bartos Theater during ... , MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance ... consulting, provides a free webinar on Performing Quality Investigations: Getting to ... 12pm CT at no charge. , Incomplete investigations are still a major concern ...
Breaking Biology Technology: